Company Dossier · Health Care
Dentsply Sirona
- MidCap 400
What Dentsply Sirona is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $3.64 billion, down 0.8% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.14 billion, about level with a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.18 billion, up 20% from a year earlier.SEC EDGAR filings (XBRL)
- Long-term debt issued in the fiscal year to December 31, 2025: $0.55 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 6, 2026): sentiment -0.20 on a −1 to +1 scale (negative), confidence 0.70 of 1.Palanor Discourse
- Latest annual report (filed February 26, 2026): 0 risk factors added, 6 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net buyers in Q2 2026: $0.6 million on the open market.SEC Form 4
- 373 institutional managers reported a position at June 30, 2026 (−12 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 4 (12 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →Company Posture covers S&P 500 companies.
Credit
How these are built →No bond term sheets or tagged debt on file for Dentsply Sirona yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Dentsply Sirona, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- PositiveDentsply Sirona Continues North American Commercial Expansion with Midwest Dental Agreement
manilatimes.net · via Marketaux · Oct 6, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 12, 2026Trademark
- Oct 9, 20268-KMaterial agreement signedItem 1.01
- Oct 6, 2026Patent
- Sep 8, 2026Patent
- Sep 8, 2026Patent
- Sep 1, 2026PatentPatent granted: DENTAL PROCEDURESUS 12725254
- Sep 1, 2026Patent
- Jun 11, 20268-KDirector or officer changeItem 5.02
- Jun 4, 20268-KShareholder vote resultsItem 5.07
- Feb 26, 202610-KAnnual report (10-K)0 risk factors added, 6 removed
- Feb 24, 20268-KDirector or officer changeItem 5.02
- Jan 27, 2026Trademark
- Jan 22, 2026LobbyingLobbying report (DENTSPLY SIRONA INC.)fourth_quarter 2025 · $0.0 million
- Jan 20, 2026LobbyingLobbying report (DENTSPLY SIRONA INC.)fourth_quarter 2025
- Jan 13, 20268-KDirector or officer changeItem 5.02
- Dec 31, 20258-KMaterial agreement signedItem 1.01
- Dec 19, 2025LobbyingLobbying report (FORBES-TATE)fourth_quarter 2025 · $0.1 million
- Nov 7, 20258-KDirector or officer changeItem 5.02
- Nov 6, 20258-KDirector or officer changeItem 5.02
- Oct 29, 2025Trademark
- Oct 29, 2025Trademark
- Oct 18, 2025LobbyingLobbying report (FORBES-TATE)third_quarter 2025 · $0.1 million
- Oct 15, 2025LobbyingLobbying report (DENTSPLY SIRONA INC.)third_quarter 2025 · $0.0 million
- Oct 3, 20258-KDirector or officer changeItem 5.02
- Sep 19, 20258-KDirector or officer changeItem 5.02
- Jul 21, 20258-KDirector or officer changeItem 5.02
- Jul 18, 2025LobbyingLobbying report (DENTSPLY SIRONA INC.)second_quarter 2025 · $0.1 million
- Jul 17, 2025LobbyingLobbying report (FORBES-TATE)second_quarter 2025 · $0.1 million
- Jun 12, 20258-KMaterial agreement signedItem 1.01
- Jun 12, 20258-KMaterial agreement terminatedItem 1.02
- Jun 4, 20258-KMaterial agreement signedItem 1.01
- May 29, 20258-KDirector or officer changeItem 5.02
- May 22, 20258-KShareholder vote resultsItem 5.07
- Apr 18, 2025LobbyingLobbying report (FORBES-TATE)first_quarter 2025 · $0.0 million
- Mar 19, 20258-KMaterial agreement signedItem 1.01
- Feb 27, 202510-KAnnual report (10-K)1 risk factors added, 2 removed
- Feb 6, 20258-KDirector or officer changeItem 5.02
- Nov 7, 20248-KDirector or officer changeItem 5.02
- Feb 29, 202410-KAnnual report (10-K)2 risk factors added, 5 removed
Peers
Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Alnylam Pharmaceuticals ALNY | $3.7B | $0.5B | Dec 31, 2025 |
| Bruker BRKR | $3.5B | $0.1B | Jun 30, 2026 |
| Veeva Systems VEEV | $3.5B | — | Jul 31, 2026 |
| BioMarin Pharmaceutical BMRN | $3.4B | $0.7B | Jun 30, 2026 |
| Neurocrine Biosciences NBIX | $3.4B | $0.6B | Jun 30, 2026 |
| West Pharmaceutical Services WST | $3.3B | $0.4B | Jun 30, 2026 |
| Charles River Laboratories CRL | $4.0B | $0.4B | Jun 27, 2026 |
| Mettler Toledo MTD | $4.1B | $0.9B | Jun 30, 2026 |